RT Journal Article
SR Electronic
T1 Neuroinflammation predicts disease progression in progressive supranuclear palsy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.19.20106393
DO 10.1101/2020.05.19.20106393
A1 Malpetti, Maura
A1 Passamonti, Luca
A1 Jones, P. Simon
A1 Street, Duncan
A1 Rittman, Timothy
A1 Fryer, Tim D.
A1 Hong, Young T.
A1 Rodríguez, Patricia Vázquez
A1 Bevan-Jones, W. Richard
A1 Aigbirhio, Franklin I.
A1 O’Brien, John T.
A1 Rowe, James B.
YR 2020
UL http://medrxiv.org/content/early/2020/05/26/2020.05.19.20106393.abstract
AB Objective In addition to tau pathology and neuronal loss, neuroinflammation occurs in progressive supranuclear palsy (PSP). We test the hypotheses that baseline in vivo assessments of regional neuroinflammation ([11C]PK11195 PET), tau pathology ([18F]AV-1451 PET), and atrophy (structural MRI) predict disease progression.Methods Seventeen patients with PSP-Richardson’s syndrome underwent a baseline multi-modal imaging assessment. Disease severity was measured at baseline and serially up to 4 years with the PSP-rating-scale (average interval 5 months). Regional grey-matter volumes and PET ligand binding potentials were summarised by three Principal Component Analyses (PCAs). A linear mixed effects model was applied to the longitudinal PSP-rating-scale scores. Single-modality imaging predictors were regressed against the individuals’ estimated rate of progression to identify the prognostic value of baseline imaging markers.Results The PCA factors reflecting neuroinflammation and tau burden in the brainstem and cerebellum correlated with the subsequent annual rate of change in the PSP-rating-scale. PCA-derived PET markers of neuroinflammation and tau pathology correlated with brain atrophy in the same regions. However, MRI markers of brain atrophy alone did not predict clinical progression.Conclusions Molecular imaging with PET can predict clinical progression in PSP. These data encourage the evaluation of immunomodulatory approaches to disease-modifying therapies in PSP, and the potential for PET to stratify patients for early phase clinical trials.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was co-funded by the National Institute for Health Research Cambridge Biomedical Research Centre and Biomedical Research Unit in Dementia (NIHR) [RG64473]; the PSP Association (“MAPT-PSP”); the Wellcome Trust [103838]; the Cambridge Trust & Sidney Sussex College Scholarship; the Medical Research Council [MR/P01271X/1]; and the Cambridge Centre for Parkinson-Plus.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymized data may be shared through the Dementias Platform UK Portal by request to the senior author from a qualified investigator for non-commercial use (data sharing is subject to participants’ consent and GDPR regulations).